FDA Moves to Schedule Kratom’s Most Potent Compound as Opioid Risk Concerns Grow

The Food and Drug Administration has formally initiated steps to classify 7-hydroxymitragynine (7-OH) — the most potent opioid-active alkaloid in the kratom plant — as a Schedule I controlled substance, recommending the DEA begin rulemaking to add it to the Controlled Substances Act.

What’s Being Targeted

7-OH is found in natural kratom leaf at low concentrations, but commercial kratom products — particularly capsules, extracts, and shots — often contain concentrations far above what occurs naturally. The FDA’s enforcement action is specifically focused on these elevated-7-OH products, not the natural kratom leaf itself. The DEA will open a public comment period before any scheduling takes effect.

Congressional pressure has accelerated the timeline. Senators Pete Ricketts (R-NE) and Richard Blumenthal (D-CT) wrote to the FDA Commissioner in March 2026 urging scheduling of both 7-OH and the whole kratom leaf. California has moved the fastest at the state level, achieving 95% retail compliance after directing removal of more than 3,308 kratom and 7-OH products from store shelves.

Why This Matters for People in Recovery

Kratom occupies a gray zone that matters deeply to the recovery community. Many people with opioid use disorder have used kratom — often self-directed — to manage withdrawal symptoms or reduce opioid use. Scheduling 7-OH-concentrated products removes the most pharmacologically risky form of the product from shelves. But it also means people who have relied on kratom as part of an informal recovery strategy may face disruption without alternative support in place. Rize Recovery can help you find evidence-based treatment resources at rizerecovery.com/find-help.